The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
The VHL/HIF axis in clear cell renal carcinoma
Open accessAbstract
Inactivation of the VHL tumor suppressor protein (pVHL) is a common event in clear cell renal carcinoma, which is the most common form of kidney cancer. pVHL performs many functions, including serving as the substrate recognition module of an ubiquitin ligase complex that targets the alpha subunits of the heterodimeric HIF transcription factor for proteasomal degradation. Deregulation of HIF2α appears to be a driving force in pVHL-defective clear cell renal carcinomas. In contrast, genetic and functional studies suggest that HIF1α serves as a tumor suppressor and is a likely target of the 14q deletions that are characteristic of this tumor type. Drugs that inhibit HIF2α, or its downstream targets such as VEGF, are in various stages of clinical testing. Indeed, clear cell renal carcinomas are exquisitely sensitive to VEGF deprivation and four VEGF inhibitors have now been approved for the treatment of this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909353106 · Cited by 451
RetractedSunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
Self-citationMotzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., Barrios, C. H., Salman, P., Gladkov, O. A., Kavina, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9764 · Cited by 2,471
Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,217
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693
Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598
Lando, D., Peet, D. J., Gorman, J. J., Whelan, D. A., Whitelaw, M. L., & Bruick, R. K. (2002) · Genes & Development · doi:10.1101/gad.991402 · Cited by 1,550
Mahon, P. C., Hirota, K., & Semenza, G. L. (2001) · Genes & Development · doi:10.1101/gad.924501 · Cited by 1,385
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311
Benjamin, L. E., Hemo, I., & Keshet, E. (1998) · Development · doi:10.1242/dev.125.9.1591 · Cited by 1,265
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,241
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes
Dalgliesh, G. L., Furge, K., Greenman, C., Chen, L., Bignell, G., Butler, A., Davies, H., Edkins, S., Hardy, C., Latimer, C., et al. (2010) · Nature · doi:10.1038/nature08672 · Cited by 1,173
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
Varela, I., Tarpey, P., Raine, K., Huang, D., Ong, C. K., Stephens, P., Davies, H., Jones, D., Lin, M.-L., Teague, J., et al. (2011) · Nature · doi:10.1038/nature09639 · Cited by 1,123
Gao, X., Wu, G., Gu, X., Fu, L., & Mei, C. (2013) · Kidney and Blood Pressure Research · doi:10.1159/000355743 · Cited by 1,035
Oxygen Sensing, Homeostasis, and Disease
Semenza, G. L. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011165 · Cited by 993
Role of VHL Gene Mutation in Human Cancer
Kim, W. Y., & Kaelin, W. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.061 · Cited by 943
Self-citationRaval, R. R., Lau, K. W., Tran, M. G. B., Sowter, H. M., Mandriota, S. J., Li, J.-L., Pugh, C. W., Maxwell, P. H., Harris, A. L., & Ratcliffe, P. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5675-5686.2005 · Cited by 940
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938
Molecular basis of the VHL hereditary cancer syndrome
Kaelin, W. G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc885 · Cited by 865
Self-citationCovello, K. L., Kehler, J., Yu, H., Gordan, J. D., Arsham, A. M., Hu, C.-J., Labosky, P. A., Simon, M. C., & Keith, B. (2006) · Genes & Development · doi:10.1101/gad.1399906 · Cited by 821
HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation
Yu, F., White, S. B., Zhao, Q., & Lee, F. S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181341498 · Cited by 796
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761
Self-citationHewitson, K. S., McNeill, L. A., Riordan, M. V., Tian, Y.-M., Bullock, A. N., Welford, R. W., Elkins, J. M., Oldham, N. J., Bhattacharya, S., Gleadle, J. M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200273200 · Cited by 719
Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression
Makino, Y., Cao, R., Svensson, K., Bertilsson, G., Asman, M., Tanaka, H., Cao, Y., Berkenstam, A., & Poellinger, L. (2001) · Nature · doi:10.1038/35107085 · Cited by 705
Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth
Kondo, K., Kim, W. Y., Lechpammer, M., & Kaelin, W. G. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000083 · Cited by 611
Self-citationHypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo
Rankin, E. B., Biju, M. P., Liu, Q., Unger, T. L., Rha, J., Johnson, R. S., Simon, M. C., Keith, B., & Haase, V. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30117 · Cited by 596
Ivan, M., Haberberger, T., Gervasi, D. C., Michelson, K. S., Günzler, V., Kondo, K., Yang, H., Sorokina, I., Conaway, R. C., Conaway, J. W., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192342099 · Cited by 561
Self-citationAmino Acid and Insulin Signaling via the mTOR/p70 S6 Kinase Pathway
Tremblay, F., & Marette, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106703200 · Cited by 542
Maher, E. R., & Kaelin, W. G. (1997) · Medicine · doi:10.1097/00005792-199711000-00001 · Cited by 528
Self-citationHIF-α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma
Gordan, J. D., Lal, P., Dondeti, V. R., Letrero, R., Parekh, K. N., Oquendo, C. E., Greenberg, R. A., Flaherty, K. T., Rathmell, W. K., Keith, B., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.016 · Cited by 493
HIF activation identifies early lesions in VHL kidneys
Mandriota, S. J., Turner, K. J., Davies, D. R., Murray, P. G., Morgan, N. V., Sowter, H. M., Wykoff, C. C., Maher, E. R., Harris, A. L., Ratcliffe, P. J., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00071-5 · Cited by 483
Liu, Y. V., Baek, J. H., Zhang, H., Diez, R., Cole, R. N., & Semenza, G. L. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.01.001 · Cited by 478
Smith, K., Gunaratnam, L., Morley, M., Franovic, A., Mekhail, K., & Lee, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0169 · Cited by 458
Koivunen, P., Hirsilä, M., Günzler, V., Kivirikko, K. I., & Myllyharju, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312254200 · Cited by 447
Maranchie, J. K., Vasselli, J. R., Riss, J., Bonifacino, J. S., Linehan, W. M., & Klausner, R. D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00044-2 · Cited by 432
Genetic and Functional Studies Implicate HIF1 α as a 14q Kidney Cancer Suppressor Gene
Shen, C., Beroukhim, R., Schumacher, S. E., Zhou, J., Chang, M., Signoretti, S., & Kaelin, W. G. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0098 · Cited by 413
Self-citationBeroukhim, R., Brunet, J.-P., Di Napoli, A., Mertz, K. D., Seeley, A., Pires, M. M., Linhart, D., Worrell, R. A., Moch, H., Rubin, M. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0146 · Cited by 412
Self-citationXia, X., Lemieux, M. E., Li, W., Carroll, J. S., Brown, M., Liu, X. S., & Kung, A. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810067106 · Cited by 410
The hypoxic response of tumors is dependent on their microenvironment
Blouw, B., Song, H., Tihan, T., Bosze, J., Ferrara, N., Gerber, H.-P., Johnson, R. S., & Bergers, G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00194-6 · Cited by 408
Histone demethylases in development and disease
Pedersen, M. T., & Helin, K. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.08.011 · Cited by 392
Hoffman, M. A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1019 · Cited by 382
Makino, Y., Kanopka, A., Wilson, W. J., Tanaka, H., & Poellinger, L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200328200 · Cited by 375
Clifford, S. C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1029 · Cited by 373
Hu, C.-J., Sataur, A., Wang, L., Chen, H., & Simon, M. C. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-05-0419 · Cited by 355
Carroll, V. A., & Ashcroft, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2519 · Cited by 352
Beyer, S., Kristensen, M. M., Jensen, K. S., Johansen, J. V., & Staller, P. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804578200 · Cited by 340
Hypoxia-inducible factor 2 regulates hepatic lipid metabolism
Rankin, E. B., Rha, J., Selak, M. A., Unger, T. L., Keith, B., Liu, Q., & Haase, V. H. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00200-09 · Cited by 338
Kaelin, W. G. (2007) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.2.010506.092049 · Cited by 336
Self-citationKrieg, A. J., Rankin, E. B., Chan, D., Razorenova, O., Fernandez, S., & Giaccia, A. J. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00444-09 · Cited by 334
Histone lysine methylation and demethylation pathways in cancer
Varier, R. A., & Timmers, H. T. M. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.10.002 · Cited by 334
Rowinsky, E. K., Schwartz, G. H., Gollob, J. A., Thompson, J. A., Vogelzang, N. J., Figlin, R., Bukowski, R., Haas, N., Lockbaum, P., Li, Y.-P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.061 · Cited by 329
Bukowski, R. M., Kabbinavar, F. F., Figlin, R. A., Flaherty, K., Srinivas, S., Vaishampayan, U., Drabkin, H. A., Dutcher, J., Ryba, S., Xia, Q., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5154 · Cited by 315
Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2
Toschi, A., Lee, E., Gadir, N., Ohh, M., & Foster, D. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.c800170200 · Cited by 301
Feldman, D. R., Baum, M. S., Ginsberg, M. S., Hassoun, H., Flombaum, C. D., Velasco, S., Fischer, P., Ronnen, E., Ishill, N., Patil, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.0108 · Cited by 298
Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1α
Pollard, P. J., Loenarz, C., Mole, D. R., McDonough, M. A., Gleadle, J. M., Schofield, C. J., & Ratcliffe, P. J. (2008) · Biochemical Journal · doi:10.1042/bj20081238 · Cited by 295
Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
Hutson, T. E., Davis, I. D., Machiels, J.-P. H., De Souza, P. L., Rottey, S., Hong, B.-F., Epstein, R. J., Baker, K. L., McCann, L., Crofts, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6994 · Cited by 295
Dayan, F., Roux, D., Brahimi-Horn, M. C., Pouyssegur, J., & Mazure, N. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4564 · Cited by 294
Maynard, M. A., Qi, H., Chung, J., Lee, E. H. L., Kondo, Y., Hara, S., Conaway, R. C., Conaway, J. W., & Ohh, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208681200 · Cited by 283
Franovic, A., Gunaratnam, L., Smith, K., Robert, I., Patten, D., & Lee, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702387104 · Cited by 250
Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL−/− tumors
Zimmer, M., Doucette, D., Siddiqui, N., & Iliopoulos, O. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.89.2.2 · Cited by 244
VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400
Young, A. P., Schlisio, S., Minamishima, Y. A., Zhang, Q., Li, L., Grisanzio, C., Signoretti, S., & Kaelin, W. G. (2008) · Nature Cell Biology · doi:10.1038/ncb1699 · Cited by 239
Self-citationPurdue, M. P., Johansson, M., Zelenika, D., Toro, J. R., Scelo, G., Moore, L. E., Prokhortchouk, E., Wu, X., Kiemeney, L. A., Gaborieau, V., et al. (2011) · Nature Genetics · doi:10.1038/ng.723 · Cited by 237
Failure to prolyl hydroxylate hypoxia‐inducible factor α phenocopies VHL inactivation in vivo
Kim, W. Y., Safran, M., Buckley, M. R., Ebert, B. L., Glickman, J., Bosenberg, M., Regan, M., & Kaelin, W. G. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601300 · Cited by 235
Bracken, C. P., Fedele, A. O., Linke, S., Balrak, W., Lisy, K., Whitelaw, M. L., & Peet, D. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600288200 · Cited by 222
Olenyuk, B. Z., Zhang, G.-J., Klco, J. M., Nickols, N. G., Kaelin, W. G., & Dervan, P. B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407617101 · Cited by 219
Self-citationCytogenetic Profile Predicts Prognosis of Patients With Clear Cell Renal Cell Carcinoma
Klatte, T., Rao, P. N., de Martino, M., LaRochelle, J., Shuch, B., Zomorodian, N., Said, J., Kabbinavar, F. F., Belldegrun, A. S., & Pantuck, A. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8345 · Cited by 215
Stadler, W. M., Vogelzang, N. J., Amato, R., Sosman, J., Taber, D., Liebowitz, D., & Vokes, E. E. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.2.371 · Cited by 208
Koochekpour, S., Jeffers, M., Wang, P. H., Gong, C., Taylor, G. A., Roessler, L. M., Stearman, R., Vasselli, J. R., Stetler-Stevenson, W. G., Kaelin, W. G., et al. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.5902 · Cited by 201
Self-citationHIF2α inhibition promotes p53 pathway activity, tumor cell death, and radiation responses
Bertout, J. A., Majmundar, A. J., Gordan, J. D., Lam, J. C., Ditsworth, D., Keith, B., Brown, E. J., Nathanson, K. L., & Simon, M. C. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907357106 · Cited by 196
Yan, Q., Bartz, S., Mao, M., Li, L., & Kaelin, W. G. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01514-06 · Cited by 193
Self-citationHypoxia upregulates the histone demethylase JMJD1A via HIF-1
Wellmann, S., Bettkober, M., Zelmer, A., Seeger, K., Faigle, M., Eltzschig, H. K., & Bührer, C. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.05.150 · Cited by 193
Maynard, M. A., Evans, A. J., Hosomi, T., Hara, S., Jewett, M. A. S., & Ohh, M. (2005) · The FASEB Journal · doi:10.1096/fj.05-3788com · Cited by 193
Regulation of endocytosis via the oxygen-sensing pathway
Wang, Y., Roche, O., Yan, M. S., Finak, G., Evans, A. J., Metcalf, J. L., Hast, B. E., Hanna, S. C., Wondergem, B., Furge, K. A., et al. (2009) · Nature Medicine · doi:10.1038/nm.1922 · Cited by 192
Cho, D. C., Cohen, M. B., Panka, D. J., Collins, M., Ghebremichael, M., Atkins, M. B., Signoretti, S., & Mier, J. W. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3022 · Cited by 192
Zimmer, M., Ebert, B. L., Neil, C., Brenner, K., Papaioannou, I., Melas, A., Tolliday, N., Lamb, J., Pantopoulos, K., Golub, T., et al. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.12.004 · Cited by 191
Koh, M. Y., Darnay, B. G., & Powis, G. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00773-08 · Cited by 182
Burrows, A. E., Smogorzewska, A., & Elledge, S. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009559107 · Cited by 172
Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
Knebelmann, B., Karumanchi, S. A., Cohen, H. T., & Sukhatme, V. P. (1998) · PubMed · Cited by 170
BAF180 Is a Critical Regulator of p21 Induction and a Tumor Suppressor Mutated in Breast Cancer
Xia, W., Nagase, S., Montia, A. G., Kalachikov, S. M., Keniry, M., Su, T., Memeo, L., Hibshoosh, H., & Parsons, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5276 · Cited by 165
Stolze, I. P., Tian, Y.-M., Appelhoff, R. J., Turley, H., Wykoff, C. C., Gleadle, J., & Ratcliffe, P. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406713200 · Cited by 164
Mydlo, J. H., Michaeli, J., Cordon‐Cardo, C., Goldenberg, A. S., Heston, W. D. W., & Fair, W. R. (1989) · PubMed · Cited by 158
Niu, X., Zhang, T., Liao, L., Zhou, L., Lindner, D. J., Zhou, M., Rini, B. I., Yan, Q., & Yang, H. (2011) · Oncogene · doi:10.1038/onc.2011.266 · Cited by 157
Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice
Rankin, E. B., Rha, J., Unger, T. L., Wu, C., Shutt, H. P., Johnson, R. S., Simon, M. C., Keith, B., & Haase, V. H. (2008) · Oncogene · doi:10.1038/onc.2008.160 · Cited by 149
Zatyka, M., da Silva, N. F., Clifford, S. C., Morris, M. R., Wiesener, M. S., Eckardt, K., Houlston, R. S., Richards, F. M., Latif, F., & Maher, E. R. (2002) · PubMed · doi:10.25405/ncl.34582002 · Cited by 147
Bommi‐Reddy, A., Almeciga, I., Sawyer, J., Geisen, C., Li, W., Harlow, E., Kaelin, W. G., & Grueneberg, D. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806574105 · Cited by 141
Self-citationRankin, E. B., Higgins, D. F., Walisser, J. A., Johnson, R. S., Bradfield, C. A., & Haase, V. H. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.8.3163-3172.2005 · Cited by 140
Monzon, F. A., Alvarez, K., Peterson, L. E., Truong, L. D., Amato, R. J., Hernandez-McClain, J., Tannir, N. M., Parwani, A. V., & Jonasch, E. W. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.107 · Cited by 138
Human cancers converge at the HIF-2α oncogenic axis
Franovic, A., Holterman, C. E., Payette, J., & Lee, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906432106 · Cited by 135
Bento, C. F., Fernandes, R., Ramalho, J. S., Marques, C., Shang, F., Taylor, A., & Pereira, P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015062 · Cited by 134
Modulating Hypoxia-Inducible Transcription by Disrupting the HIF-1–DNA Interface
Nickols, N. G., Jacobs, C. S., Farkas, M. E., & Dervan, P. B. (2007) · ACS Chemical Biology · doi:10.1021/cb700110z · Cited by 128
VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells.
Bindra, R. S., Vasselli, J. R., Stearman, R. S., Linehan, W. M., & Klausner, R. D. (2002) · PubMed · Cited by 127
Baba, M., Hirai, S., Yamada‐Okabe, H., Hamada, K., Tabuchi, H., Kobayashi, K., Kondo, K., Yoshida, M., Yamashita, A., Kishida, T., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206373 · Cited by 112
LOT1 (ZAC1/PLAGL1) and its family members: Mechanisms and functions
Abdollahi, A. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20835 · Cited by 111
Li, L., Zhang, L., Zhang, X., Yan, Q., Minamishima, Y. A., Olumi, A. F., Mao, M., Bartz, S. R., & Kaelin, W. G. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00282-07 · Cited by 111
Self-citationUhlman, D. L., Nguyen, P., Manivel, J. C., Zhang, G., Hagen, K., Fraley, E. E., Aeppli, D. M., & Niehans, G. A. (1995) · PubMed · Cited by 111
A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell Carcinoma
Dawson, N. A., Guo, C., Zak, R. D., Dorsey, B., Smoot, J., Wong, J. K. M., & Hussain, A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0310 · Cited by 110
Mock, H., Sauter, G., Buchholz, N. P. N., Gasser, T. C., Bubendorf, L., Waldman, F., & Mihatsch, M. J. (1997) · Human Pathology · doi:10.1016/s0046-8177(97)90198-2 · Cited by 100
Nakaigawa, N., Yao, M., Baba, M., Kato, S., Kishida, T., Hattori, K., Nagashima, Y., & Kubota, Y. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0617 · Cited by 90
Petrides, P. E., Bock, S., Bovens, J., Hofmann, R. W., & Jakse, G. (1990) · PubMed · Cited by 89
Roberts, A. M., Watson, I. R., Evans, A. J., Foster, D. A., Irwin, M. S., & Ohh, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1770 · Cited by 88
Hainsworth, J. D., Spigel, D. R., Sosman, J. A., Burris, H. A., Farley, C., Cucullu, H., Yost, K., Hart, L. L., Sylvester, L., Waterhouse, D. M., et al. (2007) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2007.n.030 · Cited by 80
Zhang, Y.-W., Staal, B., Essenburg, C. J., Su, Y., Kang, L., West, R. A., Kaufman, D. W., DeKoning, T., Eagleson, B., Buchanan, S. G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0898 · Cited by 80
Montani, M., Heinimann, K., von Teichman, A., Rudolph, T. J., Perren, A. A., & Moch, H. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181ddf54d · Cited by 74
Molecular Pathways in Renal Cell Carcinoma—Rationale for Targeted Treatment
KIM, W., & KAELINJR, W. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.06.001 · Cited by 73
Epidermal Growth Factor in the Normal and Neoplastic Kidney and Bladder
Lau, J. L. T., Fowler, J. E., & Ghosh, L. (1988) · The Journal of Urology · doi:10.1016/s0022-5347(17)42347-0 · Cited by 60
Schraml, P., Struckmann, K., Bednar, R., Fu, W., Gasser, T., Wilber, K., Kononen, J., Sauter, G., Mihatsch, M. J., & Moch, H. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64001-1 · Cited by 58
Song, L.-P., Zhang, J., Wu, S.-F., Huang, Y., Zhao, Q., CAO, J. C., Wu, Y.-L., Wang, L., & Chen, G.-Q. (2007) · Oncogene · doi:10.1038/sj.onc.1210670 · Cited by 58
Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma.
Morris, M. R., Hughes, D. J., Tian, Y.-M., Ricketts, C. J., Lau, K. W., Gentle, D., Shuib, S., Serrano‐Fernández, P., Lubiński, J., Wiesener, M. S., et al. (2009) · PubMed · Cited by 58
Furge, K. A., Tan, M.-H., Dykema, K. J., Kort, E. J., Stadler, W. M., Yao, X., Zhou, M., & Teh, B. T. (2007) · Oncogene · doi:10.1038/sj.onc.1210256 · Cited by 53
Combination targeted therapy in advanced renal cell carcinoma
Sosman, J. A., & Puzanov, I. J. (2009) · Cancer · doi:10.1002/cncr.24234 · Cited by 46
Amornphimoltham, P., Patel, V., Leelahavanichkul, K., Abraham, R. T., & Gutkind, J. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1756 · Cited by 45
Toxicity of Sunitinib Plus Bevacizumab in Renal Cell Carcinoma
Rini, B. I., Garcia, J. A., Cooney, M. M., Elson, P. J., Tyler, A. J., Beatty, K., Bokar, J. A., Ivy, P. S., Chen, H. X., Dowlati, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1759 · Cited by 45
Zimmer, M., Lamb, J., Ebert, B. L., Lynch, M. C., Neil, C. R., Schmidt, E. V., Golub, T. R., & Iliopoulos, O. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2877 · Cited by 40
Sar, A., Ponjevic, D., Nguyen, M., Box, A. H., & Demetrick, D. J. (2009) · Cell and Tissue Research · doi:10.1007/s00441-009-0805-y · Cited by 40
Welford, S. M., Dorie, M. J., Li, X., Haase, V. H., & Giaccia, A. J. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01618-09 · Cited by 40
Ramp, U., Jaquet, K., Reinecke, P., Schardt, C., Friebe, U., Nitsch, T., Marx, N., Gabbert, H. E., & Gerharz, C. (1997) · The Journal of Urology · doi:10.1016/s0022-5347(01)64778-5 · Cited by 37
Frequent loss of heterozygosity at 6q in pheochromocytoma
Lemeta, S., Salmenkivi, K., Pylkkänen, L., et al. (2006) · Human Pathology · doi:10.1016/j.humpath.2006.02.002 · Cited by 33
Zhang, J., Song, L., Huang, Y., Zhao, Q. L., Zhao, K.-W., & Chen, G. (2008) · Haematologica · doi:10.3324/haematol.13096 · Cited by 30
Viger, A., & Dervan, P. B. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.08.028 · Cited by 28
Woldemichael, G. M., Vasselli, J. R., Gardella, R. S., McKee, T. C., Linehan, W. M., & McMahon, J. B. (2006) · SLAS DISCOVERY · doi:10.1177/1087057106289234 · Cited by 27
Ramp, U., Reinecke, P., Gabbert, H. E., & Gerharz, C. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00030-7 · Cited by 26
Grkovic, T., Whitson, E. L., Rabe, D. C., Gardella, R. S., Bottaro, D. P., Linehan, W. M., McMahon, J. B., Gustafson, K. R., & McKee, T. C. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.127 · Cited by 26
Hypoxia-HIF-1α-C/EBPα/Runx1 signaling in leukemic cell differentiation
Zhang, J., & Chen, G. (2009) · Pathophysiology · doi:10.1016/j.pathophys.2009.02.005 · Cited by 22
Vinson, C. (2005) · Science s STKE · doi:10.1126/stke.2842005pe23 · Cited by 7
Cited by
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
Choueiri, T. K., Escudier, B., Powles, T., Mainwaring, P. N., Rini, B. I., Donskov, F., Hammers, H., Hutson, T. E., Lee, J.-L., Peltola, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510016 · Cited by 1,239
Hypoxia-Inducible Factors: Master Regulators of Cancer Progression
Schito, L., & Semenza, G. L. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.016 · Cited by 962
Endogenous tRNA-Derived Fragments Suppress Breast Cancer Progression via YBX1 Displacement
Goodarzi, H., Liu, X., Nguyen, H. C. B., Zhang, S., Fish, L., & Tavazoie, S. F. (2015) · Cell · doi:10.1016/j.cell.2015.02.053 · Cited by 949
Zou, Y., Palte, M. J., Deik, A. A., Li, H., Eaton, J. K., Wang, W., Tseng, Y.-Y., Deasy, R., Kost-Alimova, M., Dančík, V., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09277-9 · Cited by 887
Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity
Dahia, P. L. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3648 · Cited by 545
Metadata
- Authors
- Shen, C., & Kaelin, W. G.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2013-02
- Volume
- 23
- Issue
- 1
- Pages
- 18-25
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2094518946
- Cited by
- 388
- References
- 139
- FWCI
- 7.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.